Welcome to our dedicated page for Silence Therapeutics news (Ticker: SLN), a resource for investors and traders seeking the latest updates and insights on Silence Therapeutics stock.
Silence Therapeutics plc develops siRNA therapies through its proprietary mRNAi GOLD platform and trades in the U.S. through American Depositary Shares under SLN. Company news commonly covers clinical and preclinical updates for RNA-silencing programs in cardiovascular disease, hematology and rare diseases, along with financial results, research presentations and collaboration activity.
Recurring pipeline coverage centers on divesiran, a wholly owned siRNA candidate targeting TMPRSS6 for polycythemia vera, including SANRECO study updates and its FDA Fast Track and Orphan Drug designations. Updates also address platform-derived programs such as SLN312, AstraZeneca collaboration matters, balance-sheet commentary and board or executive changes.
Silence Therapeutics (Nasdaq: SLN) closed its previously announced upsized underwritten public offering of 14,907,407 ADSs, including the underwriters’ full exercise of their option to purchase 1,944,444 additional ADSs. Each ADS represents three ordinary shares.
The ADSs were sold in the United States at a public offering price of $13.50 per ADS, generating gross proceeds of approximately $201.3 million before underwriting discounts, commissions and other offering expenses. Jefferies, Morgan Stanley, Cantor and William Blair acted as joint book-running managers. The transaction was conducted under an effective shelf registration statement and related prospectus filings with the U.S. Securities and Exchange Commission.
Silence Therapeutics (NASDAQ: SLN) has priced an upsized underwritten public offering of 12,962,963 American Depositary Shares (ADSs), each representing three ordinary shares, at a public offering price of $13.50 per ADS in the United States.
The company expects gross proceeds of approximately $175 million before underwriting discounts, commissions and expenses, excluding any exercise of the underwriters’ 30‑day option to purchase up to 1,944,444 additional ADSs at the same public price. The offering is expected to close on or about August 13, 2026, subject to customary closing conditions. Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book‑running managers. The ADSs are being offered under an effective shelf registration statement and related prospectus supplements filed with the U.S. SEC.
Silence Therapeutics (NASDAQ: SLN) has commenced an underwritten public offering of approximately $150 million of American Depositary Shares (ADSs), with each ADS representing three ordinary shares. All ADSs will be offered by the company in a U.S. public offering registered under the Securities Act.
According to Silence Therapeutics, the underwriters will receive a 30-day option to purchase up to an additional 15% of the total ADSs at the public offering price, less underwriting discounts and commissions. Jefferies, Morgan Stanley, Cantor and William Blair are acting as joint book-running managers. The deal relies on an effective Form S-3 shelf registration and will be made only by prospectus supplement and accompanying prospectus, subject to market and other conditions.
Silence Therapeutics (Nasdaq: SLN) reported positive topline results from the Phase 2 SANRECO trial of divesiran in 48 phlebotomy-dependent polycythemia vera (PV) patients. The 36-week randomized, double-blind, placebo-controlled study of divesiran 6 mg/kg given subcutaneously every six or twelve weeks met its primary and key secondary endpoints.
Clinical response was achieved in 88% of divesiran-treated patients versus 19% on placebo (p<0.0001), with response rates of 93.8% (Q6W) and 81.3% (Q12W). Mean phlebotomies per patient were 0.2 on divesiran versus 2.1 on placebo (p<0.0001). Divesiran was observed to be well tolerated with no new safety findings, and a Phase 3 PV trial of Q12W dosing is anticipated to start in 1H 2027.
Silence Therapeutics (Nasdaq: SLN) reported second quarter 2026 results, highlighting progress in its siRNA pipeline and lower operating losses for the period ended June 30, 2026. Cash and cash equivalents were $72.1 million. Revenue was $0 versus $224,000 in the second quarter of 2025.
Research and development expenses decreased to $9.1 million from $17.6 million year over year, mainly due to completion of zerlasiran Phase 3 readiness in 2025 and reduced personnel costs. General and administrative expenses declined to $4.7 million from $5.1 million. Net loss narrowed to $12.3 million, or $0.09 per share, compared with $27.4 million, or $0.19 per share.
According to the company, key business milestones included Phase 1 and 2 advances for divesiran in polycythemia vera, Phase 1 data for SLN312 (AZD1705) under the AstraZeneca collaboration showing favorable safety and durable ANGPTL3 and lipid reductions, and preclinical progress on SLN365 and SLN098 toward potential IND filings in 2027.
Silence Therapeutics (Nasdaq: SLN) announced an investor conference call and webcast to discuss topline results from the Phase 2 SANRECO trial of divesiran in polycythemia vera. The event is scheduled for Monday, August 10, 2026 at 8:00 a.m. EDT.
Investors can access the event via a dedicated conference call registration link and a separate webcast link, with a replay to be made available in the Investors section of the company website. Silence Therapeutics is a clinical-stage biotechnology company developing siRNA therapies using its mRNAi GOLD platform across rare and common diseases.
Silence Therapeutics (Nasdaq: SLN) reported follow-up Phase 1 SANRECO data for divesiran in 21 phlebotomy-dependent polycythemia vera patients at EHA 2026.
Phlebotomies fell from 80 in the prior six months to 5 on treatment and 4 in 16-week follow-up, with median 287 days to first phlebotomy among 14 patients, symptom score improvements, and a favorable safety profile. Phase 2 Q6W/Q12W topline data are expected in August 2026.
Silence Therapeutics (Nasdaq: SLN), a clinical-stage biotech developing siRNA therapies, will join an analyst-led fireside chat at the Jefferies Global Healthcare Conference on Wednesday, June 3, 2026 at 4:55 p.m. ET.
A live and archived webcast will be available in the Investors section of the company website.
Silence Therapeutics (Nasdaq: SLN), a clinical-stage siRNA therapeutics company, announced that Chief Medical Officer Curtis Rambaran, MD, will participate in a fireside chat at the H.C. Wainwright BioConnect Investor Conference on Tuesday, May 19, 2026 at 2:00 p.m. ET. A live webcast and archived replay will be available in the Investors section of the company website.
Silence Therapeutics (Nasdaq: SLN) reported Q1 2026 results and program updates on May 7, 2026. Key operational items: SANRECO Phase 2 divesiran topline results remain on-track for August 2026, and Phase 1 abstracts for divesiran and SLN312 (AZD1705) were accepted for EHA and EAS 2026 congresses in June and May. Financial highlights: cash, cash equivalents and short-term investments $70.1M, R&D expenses $9.1M, G&A $7.0M, and net loss $15.0M for Q1 2026. Total shares outstanding: 141,703,840.